摘要
目的采用Meta分析的方法评价血清p16甲基化在肺癌诊断中的价值。方法检索PubMed、ISI Web of Knowledge、Springerlink、Elsevier、OVID等数据库,检索时间截止为2010年10月,收集研究血清P16甲基化对肺癌诊断价值的相关文献;按纳入与排除标准筛选文献,并对纳入文献进行质量评价;采用MetaDisc1.4软件对数据进行异质性分析,计算汇总敏感度、特异度、汇总似然比,做汇总受试者工作特征曲线（SROC曲线）,综合评价血清P16甲基化在肺癌诊断中的价值。结果共纳入10篇文献,分析病例组肺癌患者602例,对照组530例。对入选10篇文献进行异质性检验,提示所纳入文献具有齐性,应用固定效应模型进行Meta分析。分析结果：汇总灵敏度为0.37（95%CI0.33~0.41）,汇总特异度为0.96（95%CI0.94~0.98）,汇总阳性似然比为11.51（95%CI6.84~19.36）,汇总阴性似然比为0.66（95%CI0.62~0.72）,SROC曲线下面积为0.8511。结论血清p16甲基化在肺癌的诊断中有很高的特异度和一定的灵敏度,在肺癌诊断中有一定的参考价值。
Objective Using Meta analysis to evaluate the value of p16 methylation in the diagnosis of lung cancer. Methods Articles related to the p16 methylation in the serum for the diagnosis of lung cancer, published until October 2010, were retrievalcd in the databanks including MEDLINE, ISI Web of Knowledge, Springerlink,Elsevier, OVID and CNKI. Meta-Disc 1.4 software was used to analyze data. We evaluated the diagnosis value of p16 methylation in serum from patients with lung cancer by the pooled sensitivity, the pooled specificity, the likelihood ratio（LR） and summary receiver operating characteristic curve （ SROC curve） statistical indicators. Results Ten studies met our inclusion criteria. 602 lung cancer eases and 530 controls were brought into the study. Heterogeneity test showed that the homogeneity of the study was good, so the fixed effect model was used for Meta-analysis. And the pooled sensitivity was 0. 37 （95% CI0. 3349. 41 ）, the pooled specificity was 0.96 （95 % CI0. 9449.98 ） , the positive likelihood ratio was 11.51 （ 95 % CI6. 84-19.36） , negative likelihood ratio was 0.66（95% CI0. 624）. 72） , and the SROC area under the curve （AUC） was 0. 8511. Conclusion p16 methylation in serum had a certain sensitivity and high specificity for the diagnosis of lung cancer and could be regarded as one of the reference maker.
出处
《中华肺部疾病杂志（电子版）》
CAS
2010年第2期16-20,共5页
Chinese Journal of Lung Diseases(Electronic Edition)
